Takeda & Affymax Announce Supply Agreement

The agreement allows Fresenius Medical Care North America to purchase OMONTYS for use in U.S. centers within its organization and provides for discounts and rebates on the product, subject to certain requirements.

Takeda Pharmaceuticals U.S.A. and Affymax, Inc. have announced that Takeda Pharmaceuticals America, Inc. has entered into a supply agreement for sourcing and supply of OMONTYS? (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates.

OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population with chronic kidney disease (CKD) in the United States.

The agreement, which ends in April 2013, allows Fresenius Medical Care North America to purchase OMONTYS for use in U.S. centers within its organization and provides for discounts and rebates on the product, subject to certain requirements.